Recruiting

Exercise

Sponsor:

University of British Columbia

Code:

NCT03902405

Conditions

Amphetamine-Related Disorders

Cocaine-Related Disorders

Substance-Related Disorders

Eligibility Criteria

Sex: All

Age: 19 - 70

Healthy Volunteers: Not accepted

Interventions

Active CEASAR Intervention

Placebo CEASAR

Study Details

Brief summary:

The purpose of this study is to evaluate the Computerized Exercise to Alter Stimulant Approach Responses (CEASAR), a novel stimulant use cessation intervention, for clients currently enrolled in a treatment centre for mental health and addiction. The investigators plan to conduct a randomized, single-blind controlled trial involving inpatients presenting with concurrent disorders to test the impact of this novel computerized intervention. This pilot study will be conducted at the Burnaby Centre for Mental Health and Addiction (BCMHA) in Burnaby, BC, Canada.

Conditions

Amphetamine-Related Disorders

Cocaine-Related Disorders

Substance-Related Disorders

Study ID

NCT03902405

Start date

Jun 11, 2018

Status verified date

Jun, 2021

Completion date

Mar 31, 2022

Anticipated

Primary completion date

Mar 31, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • In-patient of the Burnaby Centre of Mental Health \& Addiction
  • 19 years of age or older
  • Individuals with a current stimulant use disorder (cocaine, crack cocaine, amphetamine, methamphetamine, crystal meth), active before intake at BCMHA (as assessed by the MINI)
  • Proficiency to read and write English and competent to provide consent

Exclusion Criteria:

  • Individuals not stabilized enough to allow for regular participation in the intervention (determined by treating psychiatrist)

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Active CEASAR Intervention

Participants will be given the active CEASAR intervention where they will be trained to "avoid" cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in.

placebo comparator: Placebo CEASAR

In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.

Interventions

Active CEASAR Intervention

Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.

Placebo CEASAR

In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.

Primary outcome measure

  • Changes in craving as assessed by the Stimulant Craving Questionnaire-Brief (SCQ-B) [ Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks ]
  • Change in Behavioural association as assessed by the Behaviour Association Scale [ Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks ]
  • Relapse to use as assessed by weekly self-reports and urine drug screens [ Time Frame: Between week 2 and week 12 ]

Central Contacts and Locations

Central contacts

Anastasia Frank Cheng, MPH

604-827-4381afrank@cheos.ubc.ca

Christian Schutz, MD PhD

778-873-4785christian.schutz@ubc.ca

Locations

Burnaby Centre for Mental Health and Addiction

Recruiting

Vancouver, British Columbia, Canada, V5G 3H4

Contacts

Anastasia Frank Cheng, MPH

604-827-4381afrank@cheos.ubc.ca

Christian Schutz, MD PhD MPH

778-873-4785christian.schutz@ubc.ca

More Information

Sponsor

University of British Columbia

Last update posted

Jun 21, 2021

Last verified

Jun, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2021-06-21.